So far, quantification of SLFN11 has mainly been performed by transcript levels in cancer,1,20,21 with some protein assessment by IHC in lung,4,5,9,22 breast19 and colorectal cancer (CRC).23 Thus, a broad understanding of the correlation between SLFN11 by transcript and protein levels beyond these indications is still missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive marker to DDA and DDRi therapies. This evidence concerns the gene SLFN11 and colorectal cancer.